# Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML

> **NCT06536010** · NA · RECRUITING · sponsor: **Yang Xiaotian** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；

## Key facts

- **NCT ID:** NCT06536010
- **Lead sponsor:** Yang Xiaotian
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-03
- **Primary completion:** 2026-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536010, "Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06536010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*